<DOC>
	<DOCNO>NCT00372437</DOCNO>
	<brief_summary>Inthis study , MGCD0103 , new anticancer drug investigation , give three time weekly combination gemcitabine patient solid tumour .</brief_summary>
	<brief_title>A Phase I/II Study MGCD0103 ( MG-0103 ) Combination With Gemcitabine</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Patients must histologically cytologically documented cancer : Phase Isolid tumor gemcitabine consider standard care ; refractory solid tumor reasonable likelihood achieve clinical benefit exist therapy , fail respond standard therapy , progress despite standard therapy , standard therapy exists . Phase IIlocally advance measurable ( nonresectable III ) metastatic ( Stage IV ) pancreatic cancer . Patients know CNS metastasis may enrol Phase I II meet follow criterion : They receive radiotherapy CNS disease ; They steroids discontinue least 1 month prior study entry ; They CT MRI brain within 1 month study entry show stable disease ; ) free neurological symptom . Karnofsky performance status 70 great . Age 18 year . Laboratory requirement ( must do within 14 day prior study initiation ) : Hematology : White Blood Cells ( WBC ) ≥3 x 10 &lt; 9 &gt; /L ( ≥ 3000/mm3 ) ; Absolute Neutrophil Count ( ANC ) ≥1.5 x 10 &lt; 9 &gt; /L ( ≥1500/mm3 ) ; Platelets ≥100 x 10 &lt; 9 &gt; /L ( ≥100,000/mm3 ) ; Chemistry : Total Bilirubin ≤1.5 x Upper Limit Normal ( ULN ) ; AST ( SGOT ) ALT ( SGPT ) ≤3 x ULN ; ≤ 5 x ULN document liver metastasis ; Serum Creatinine ≤1.5 x ULN calculate creatinine clearance ≥50 mL/min ; Urinalysis : Proteinuria &lt; 1 mg/dl 500 mg protein/24 hour dipstick ≥2+ . Patients legal representative must able read ( read ) , understand , sign write informed consent ( approved institutional review board/Ethics Committee ( IRB/EC ) ) within 14 day prior start treatment . Patients another active cancer ( exclude basal cell carcinoma cervical intraepithelial neoplasia ( CIN/cervical situ melanoma situ ) . ( Phase II portion ) Pregnant lactate woman . Women child bear potential ( WOCBP ) must negative serum pregnancy test document within 7 day prior start study drug . WOCBP men whose partner WOCBP must use acceptable method contraception enrol study , period 3 month follow study drug treatment . Patients unwilling unable follow guideline exclude . Investigators follow Institutional standard regard acceptable method contraception . Patients uncontrolled concomitant illness , active infection require i.v . antibiotic , uncontrolled infection , fever &gt; 38.5C day schedule dosing . Patients serious illness , medical condition , medical history , include laboratory result , , investigator 's opinion , would likely interfere patient 's participation study , interpretation result . Patients treat investigational drug within 28 day prior study initiation ( investigational drug one approve indication ) , receive concurrent treatment experimental drug anticancer therapy . Known hypersensitivity HDAC inhibitor component MG0103 . Known hypersensitivity gemcitabine . Prior treatment gemcitabine ( expanded phase II portion ) . Known HIV know active Hepatitis B C. Any condition ( e.g. , know suspected poor compliance , psychological instability , geographical location , etc . ) , judgment investigator , may affect patient 's ability sign inform consent undergo study procedure . Any condition put patient undue risk discomfort result adherence study procedure . For example , consider requirement take MG0103 low pH drink recommendation avoid agent increase gastric pH .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Refractory solid tumor</keyword>
	<keyword>Phase I/II</keyword>
	<keyword>Refractory solid tumor</keyword>
</DOC>